UCB Results from Phase II Thrombocytopenia Trial at 2019 ASH

• Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups
• Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups
• Safety, tolerability and efficacy data support Phase III development of rozanolixizumab for primary ITP
• Rozanolixizumab’s subcutaneous route of administration could provide a new treatment option for patients with primary ITP

https://www.biospace.com/article/releases/ucb-presents-final-results-from-phase-ii-study-of-rozanolixizumab-in-primary-immune-thrombocytopenia-itp-at-2019-ash-annual-meeting/